Alpine Immune Sciences Stock Today
| ALPN Stock | USD 64.70 0.14 0.22% |
Performance20 of 100
| Odds Of DistressLess than 31
|
Alpine Immune is selling at 64.70 as of the 30th of April 2024; that is 0.22 percent up since the beginning of the trading day. The stock's open price was 64.56. Alpine Immune has about a 31 percent probability of financial distress in the next few years of operation but had a somewhat solid performance during the last 90 days. Equity ratings for Alpine Immune Sciences are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 1st of March 2024 and ending today, the 30th of April 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 17th of June 2015 | Category Healthcare | Classification Health Care |
Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmuneinflammatory disorders, and other diseases. Alpine Immune Sciences, Inc. The company has 65.56 M outstanding shares of which 4.74 M shares are presently shorted by private and institutional investors with about 1.25 trading days to cover. More on Alpine Immune Sciences
Moving against Alpine Stock
| 0.89 | EVOK | Evoke Pharma | PairCorr |
| 0.84 | ETON | Eton Pharmaceuticals Financial Report 9th of May 2024 | PairCorr |
| 0.81 | DVAX | Dynavax Technologies Financial Report 7th of May 2024 | PairCorr |
| 0.74 | ELAN | Elanco Animal Health Financial Report 14th of May 2024 | PairCorr |
| 0.59 | EGRX | Eagle Pharmaceuticals | PairCorr |
| 0.55 | EVO | Evotec SE ADR | PairCorr |
| 0.53 | EOLS | Evolus Inc Financial Report 14th of May 2024 | PairCorr |
Follow Valuation Options Odds of Bankruptcy
Financial Report 9th of May 2024
Alpine Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Alpine Immune's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Alpine Immune or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Executive CEO | Mitchell MD | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation Analysts covering Alpine Immune report their recommendations after researching Alpine Immune's financial statements, talking to executives and customers, or listening in on Alpine Immune's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Alpine Immune Sciences. The Alpine consensus assessment is calculated by taking the average forecast from all of the analysts covering Alpine Immune. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Financial Strength Based on the measurements of operating efficiency obtained from Alpine Immune's historical financial statements, Alpine Immune Sciences may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter. Financial strength of Alpine Immune Sciences is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Alpine Immune's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Alpine Immune's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Alpine Immune's financial leverage. It provides some insight into what part of Alpine Immune's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Alpine Immune Sciences (ALPN) is traded on NASDAQ Exchange in USA. It is located in 188 East Blaine Street, Seattle, WA, United States, 98102 and employs 142 people. Alpine Immune is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 4.24 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Alpine Immune's market, we take the total number of its shares issued and multiply it by Alpine Immune's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Alpine Immune Sciences conducts business under Biotechnology sector and is part of Health Care industry. The entity has 65.56 M outstanding shares of which 4.74 M shares are presently shorted by private and institutional investors with about 1.25 trading days to cover.
Alpine Immune Sciences currently holds about 167.86 M in cash with (79.01 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.52.
Check Alpine Immune Probability Of Bankruptcy
Ownership AllocationAlpine Immune Sciences retains a total of 65.56 Million outstanding shares. The majority of Alpine Immune Sciences outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Alpine Immune Sciences to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Alpine Immune. Please pay attention to any change in the institutional holdings of Alpine Immune Sciences as this could imply that something significant has changed or is about to change at the company. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.
Check Alpine Ownership Details
Alpine Stock Price Odds Analysis
Contingent on a normal probability distribution, the odds of Alpine Immune jumping above the current price in 90 days from now is roughly 2.53%. The Alpine Immune Sciences probability density function shows the probability of Alpine Immune stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 1.2143. This suggests as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Alpine Immune will likely underperform. Moreover, alpine Immune Sciences has an alpha of 1.9893, implying that it can generate a 1.99 percent excess return over NYSE Composite after adjusting for the inherited market risk (beta).
Based on a normal probability distribution, the odds of Alpine Immune to move above the current price in 90 days from now is roughly 2.53 (This Alpine Immune Sciences probability density function shows the probability of Alpine Stock to fall within a particular range of prices over 90 days) .
Alpine Stock Institutional Holders
Institutional Holdings refers to the ownership stake in Alpine Immune that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Alpine Immune's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Alpine Immune's value.| Instituion | Recorded On | Shares | |
| Franklin Resources Inc | 2023-12-31 | 1.2 M | |
| Woodline Partners Lp | 2023-12-31 | 1 M | |
| Vivo Capital, Llc | 2023-12-31 | 819.3 K | |
| Geode Capital Management, Llc | 2023-12-31 | 764.3 K | |
| Octagon Capital Advisors Lp | 2023-09-30 | 750 K | |
| Morgan Stanley - Brokerage Accounts | 2023-12-31 | 718.7 K | |
| Adage Capital Partners Gp Llc | 2023-12-31 | 714.6 K | |
| Hhg Plc | 2023-12-31 | 583.2 K | |
| Ikarian Capital, Llc | 2023-12-31 | 487.2 K | |
| Decheng Capital Llc | 2023-12-31 | 7.1 M | |
| Ra Capital Management, Llc | 2023-12-31 | 4.9 M |
Alpine Immune Historical Income Statement
Alpine Immune Sciences Income Statement is one of the three primary financial statements used for reporting Alpine's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Alpine Immune Sciences revenue and expense. Alpine Immune Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Alpine Immune's Total Revenue is very stable compared to the past year. As of the 30th of April 2024, Gross Profit is likely to grow to about 61.2 M, while Interest Expense is likely to drop about 93.1 K. View More FundamentalsAlpine Stock Against Markets
Picking the right benchmark for Alpine Immune stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Alpine Immune stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Alpine Immune is critical whether you are bullish or bearish towards Alpine Immune Sciences at a given time. Please also check how Alpine Immune's historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Alpine Immune without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Balance Of Power Now
Balance Of PowerCheck stock momentum by analyzing Balance Of Power indicator and other technical ratios |
| All Next | Launch Module |
Alpine Immune Corporate Directors
Alpine Immune corporate directors refer to members of an Alpine Immune board of directors. The board of directors generally takes responsibility for the Alpine Immune's affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Alpine Immune's board members must vote for the resolution. The Alpine Immune board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.| Paul Sekhri | Independent Director | Profile | |
| Min Cui | Director | Profile | |
| Christopher Peetz | Director | Profile | |
| Peter Thompson | Director | Profile |
How to buy Alpine Stock?
Before investing in Alpine Immune, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Alpine Immune. To buy Alpine Immune stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Alpine Immune. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Alpine Immune stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Alpine Immune Sciences stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Alpine Immune Sciences stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Alpine Immune Sciences, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Alpine Stock please use our How to Invest in Alpine Immune guide.
Already Invested in Alpine Immune Sciences?
The danger of trading Alpine Immune Sciences is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Alpine Immune is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Alpine Immune. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Alpine Immune Sciences is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Alpine Immune Sciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Alpine Immune's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Alpine Immune Sciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Alpine Immune Sciences Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alpine Immune Sciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Complementary Tools for Alpine Stock analysis
When running Alpine Immune's price analysis, check to measure Alpine Immune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alpine Immune is operating at the current time. Most of Alpine Immune's value examination focuses on studying past and present price action to predict the probability of Alpine Immune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alpine Immune's price. Additionally, you may evaluate how the addition of Alpine Immune to your portfolios can decrease your overall portfolio volatility.
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data |
Is Alpine Immune's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alpine Immune. If investors know Alpine will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alpine Immune listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.64) | Revenue Per Share 1.178 | Quarterly Revenue Growth 10.114 | Return On Assets (0.08) | Return On Equity (0.13) |
The market value of Alpine Immune Sciences is measured differently than its book value, which is the value of Alpine that is recorded on the company's balance sheet. Investors also form their own opinion of Alpine Immune's value that differs from its market value or its book value, called intrinsic value, which is Alpine Immune's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alpine Immune's market value can be influenced by many factors that don't directly affect Alpine Immune's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alpine Immune's value and its price as these two are different measures arrived at by different means. Investors typically determine if Alpine Immune is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alpine Immune's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.